Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849858 · ClinicalTrials.gov registry record · Phase 3
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
A Phase 3 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT04849858 is a Phase 3 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 13 participants.
The verdict
NCT04849858, a Phase 3 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and lowers your risk of post-operative common side effects of surgery and narcotic pain medications.
Interventions
- DRUG Bupivacaine
- DRUG Liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2023-01-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04849858
The ClinicalTrials.gov registry entry for NCT04849858 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT04849858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04849858 about?
NCT04849858 is a clinical study titled "Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures". The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and lowers your risk of post-operative common side effects of surgery and ...
What is the current status of trial NCT04849858?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2019-05-20. Estimated completion is 2023-01-13.
What interventions are being tested in trial NCT04849858?
The interventions under investigation include: Bupivacaine (DRUG), Liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT04849858?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.